Pharmacists; prescribers provide certain information to patients or their representatives on Schedule II controlled substances or opioids
Impact
The enactment of HB 1352 will amend existing regulations within Article 5 of Chapter 4 of Title 26 of the Official Code of Georgia Annotated. The intent is to establish a standardized requirement for communication between prescribers and patients related to opioid use. By emphasizing patient education on addiction risks and discussing alternative treatment options, the bill aims to reduce the potential for misuse of potent medications, ultimately promoting better health outcomes and patient autonomy in decision-making regarding their treatment options.
Summary
House Bill 1352 seeks to enhance patient safety by mandating that prescribers provide essential information regarding the use of Schedule II controlled substances and opioids prior to issuing prescriptions. The bill specifies that prescribers must inform patients, or their guardians in the case of minors, about the risks of addiction, psychological dependence, and the dangers of mixing prescribed medications with other depressants. This measure aims to ensure that patients are fully aware of the implications of their prescriptions, thereby promoting safer prescribing practices in the state.
Contention
Debate around HB 1352 might center on a few key points. Opponents may argue that the additional requirements placed on prescribers could lead to barriers in timely patient access to necessary medications. There is concern over whether the mandatory discussions may complicate the prescribing process, potentially resulting in delays that could negatively impact patients with legitimate medical needs. Proponents, however, would likely support the bill, citing the urgent need to combat the opioid crisis through improved patient awareness and education, thereby advocating responsible prescribing practices that prioritize patient safety.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.